Brevan Howard Capital Management »

Revance Therapeutics shares owned by Brevan Howard Capital Management

Quarter-by-quarter ownership of Revance Therapeutics (RVNC) shares owned by Brevan Howard Capital Management from 13F filings

Historical chart of Brevan Howard Capital Management investment in Revance Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Revance Therapeutics held by Brevan Howard Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Revance Therapeutics by Brevan Howard Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $238k 27k 8.79

More positions owned by Brevan Howard Capital Management

Ishares Msci Emerging Mkt In Msci Emg Mkt Etf (EEM)
Financial Select Sector Spdr Financial Call Option
Invesco QQQ Trust Series 1 Nasdaq100 BB:QQQ Unit Ser 1 (QQQ)
Ishares Iboxx H/y Corp Bond Iboxx Hi Yd Etf (HYG)
Consumer Staples Spdr Sbi Cons Stpls (XLP)
Ishares Russell 2000 Etf Russell 2000 Etf (IWM)
Health Care Select Secto Sbi Healthcare Call Option (XLV)
Ishares Jp Morgan Usd Emerging Markets Jpmorgan Ud Emg (EMB)
ISHARES 20plus YR TREAS 20 Yr Tr Bd Etf Call Option (TLT)
KraneShares CSI China Internet ETF Csi Chi Internet (KWEB)
Ishares Ftse/xinhua China 25 China Lg-cap Etf (FXI)
Ishares Msci Eafe Index Fund Msci Eafe Etf Put Option (EFA)
Ishares Msci Brazil Msci Brazil Etf (EWZ)
Kbw Regional Banking Etf S&p Regl Bkg Call Option (KRE)
Vnet 0 02/26 Note 2/0 (Principal)

View all positions for Brevan Howard Capital Management

Top funds holding Revance Therapeutics

Palo Alto Investors
Vanguard Group
Franklin Resources
Jpmorgan Chase & Co
Jennison Associates
Bamco
Walleye Trading Advisors
Goldman Sachs Group
Rice Hall James & Associates
Charles Schwab Investment Management
Citadel Advisors
Wellington Management Company
D. E. Shaw & Co
HighTower Advisors
Balyasny Asset Management

View all funds holding Revance Therapeutics